Autologous culture method improves retention of tumors' native properties.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
/ metabolism
Body Fluids
/ cytology
Cell Culture Techniques
/ methods
Cell Proliferation
Cell Survival
Cells, Cultured
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Models, Biological
Neoplasms
/ metabolism
Serum
/ cytology
Tissue Scaffolds
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 11 2020
24 11 2020
Historique:
received:
15
02
2020
accepted:
02
11
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
23
3
2021
Statut:
epublish
Résumé
No current in vitro tumor model replicates a tumor's in vivo microenvironment. A culturing technique that better preserves a tumor's pathophysiological conditions is needed for some important clinical applications, including personalized drug-sensitivity/resistance assays. In this study, we utilized autologous serum or body fluid to build a 3D scaffold and grow a patient's tumor. We named this technique "3D-ACM" (autologous culture method). Forty-five clinical samples from biopsies, surgically removed tumor tissues and malignant body fluids were cultured with 3D-ACM. Traditional 3D-FBS (fetal bovine serum) cultures were performed side-by-side for comparison. The results were that cells cultured in 3D-ACM rebuilt tissue-like structures, and retained their immuno-phenotypes and cytokine productions. In contrast, the 3D-FBS method promoted mesenchymal cell proliferation. In preliminary chemo drug-sensitivity assays, significantly higher mortality was always associated with FBS-cultured cells. Accordingly, 3D-ACM appears to more reliably preserve a tumor's biological characteristics, which might improve the accuracy of drug-testing for personalized cancer treatment.
Identifiants
pubmed: 33235257
doi: 10.1038/s41598-020-77238-0
pii: 10.1038/s41598-020-77238-0
pmc: PMC7686378
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20455Références
Cell. 2016 Jun 16;165(7):1586-1597
pubmed: 27315476
Elife. 2016 Nov 15;5:
pubmed: 27845624
Anticancer Res. 2015 May;35(5):2709-13
pubmed: 25964549
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Nature. 2014 Dec 18;516(7531):400-4
pubmed: 25363776
J Cell Biochem. 2001 Jun 26-Jul 25;83(1):121-8
pubmed: 11500960
Tissue Eng. 2005 Jan-Feb;11(1-2):41-9
pubmed: 15738660
Cold Spring Harb Perspect Biol. 2016 May 02;8(5):
pubmed: 27141051
J Tissue Eng Regen Med. 2015 Mar;9(3):310-4
pubmed: 23307775
Nat Med. 2017 Jul 11;23(7):796-799
pubmed: 28697178
Curr Opin Biotechnol. 2017 Oct;47:23-29
pubmed: 28578251
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Am J Pathol. 2007 Dec;171(6):2048-57
pubmed: 18055559
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Proc Natl Acad Sci U S A. 1985 Jan;82(1):119-23
pubmed: 3871521
Nat Commun. 2015 Feb 27;6:6169
pubmed: 25721094
Comb Chem High Throughput Screen. 2017;20(5):451-457
pubmed: 28155598
Front Oncol. 2015 Dec 17;5:282
pubmed: 26734568
Nature. 2015 May 7;521(7550):43-7
pubmed: 25924068
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Tissue Eng Part C Methods. 2008 Sep;14(3):261-71
pubmed: 18694322
Matrix Biol. 2009 Apr;28(3):137-47
pubmed: 19243701
J Tissue Eng. 2010 Nov 07;2010:218142
pubmed: 21350642
Cancer Res Treat. 2018 Jan;50(1):1-10
pubmed: 28903551
Physiol Rev. 2016 Jul;96(3):1025-1069
pubmed: 33003261
Curr Opin Immunol. 2017 Oct;48:15-22
pubmed: 28756233
Trends Mol Med. 2017 May;23(5):393-410
pubmed: 28341301
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
J Natl Cancer Inst. 1961 Jul;27:1-15
pubmed: 13694182